Price T Rowe Associates Inc Immunovant, Inc. Call Options Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMVT
# of Institutions
213Shares Held
63.4MCall Options Held
898KPut Options Held
656K-
Vanguard Group Inc Valley Forge, PA6.66MShares$183 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.92MShares$135 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.35MShares$120 Million4.41% of portfolio
-
Armistice Capital, LLC New York, NY3.4MShares$93.4 Million1.17% of portfolio
-
State Street Corp Boston, MA3.02MShares$83.1 Million0.0% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...